JD Supra8h
End of Semaglutide Shortage Means Big Changes for Prescribers and Compounders
On February 21, the FDA announced that the shortage of semaglutide injection products has been resolved. Semaglutide has appeared on the FDA’s ...
Modern Healthcare3h
Hims & Hers pivots as semaglutide shortage ends
Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...
pharmaphorum15h
Compounders cast adrift after semaglutide shortage ends
The end of the official shortage status for semaglutide came as telehealth company Hims & Hers – which has been pushing sales ...
Hosted on MSN18h
Hims & Hers Retail Traders Eye Robust Post-Earnings Rebound Following Stock’s Worst Drop On Semaglutide Update
Hims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...
Fierce Healthcare3d
FDA declares semaglutide shortage over, spelling end to compounded GLP-1 market, for now
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
The Ozempic Shortage Is Over
The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...
devdiscourse5h
Legal Battle Over Semaglutide Supply: Compounders vs FDA
Compounders have filed a lawsuit against the FDA challenging its decision to remove Novo Nordisk's Wegovy and Ozempic from the shortage list. The lawsuit claims the FDA's actions are arbitrary, ...
Hosted on MSN8h
What To Expect When IBD 50's No. 2, Hims & Hers, Reports Amid The Semaglutide Battle
Compounding pharmacy and IBD 50 newcomer Hims & Hers Health is expected late Monday to report bullish earnings and sales ...